Figure 4. . Comparison of impacts of ravulizumab and prior eculizumab treatment reported by caregivers of pediatric patients (n = 16).

For each statement, participants were asked to select how much they agree based on their own experience. Bar labels show the survey questions verbatim and have been grouped by negative (bar groups 1–8) and positive (bar groups 9–13) statements. It is acknowledged as a possible limitation that respondents may interpret ‘impact’ differently and not according to the intended directionality. Percentages may not sum to 100 owing to rounding.

aHUS: Atypical hemolytic uremic syndrome.

*p < 0.05; **p < 0.01.